相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
Daniel Castellano et al.
CANCER TREATMENT REVIEWS (2013)
Tyrosine Kinase Inhibitors and the Thyroid as both an Unintended and an Intended Target
Marion Vetter et al.
Endocrine Practice (2013)
Tyrosine Kinase Inhibitor-Induced Thyroid Disorders: A Review and Hypothesis
Noriko Makita et al.
THYROID (2013)
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
R. Sabatier et al.
ANNALS OF ONCOLOGY (2012)
Does Sunitinib-Induced Hypothyroidism Play a Role in the Activity of Sunitinib in Metastatic Renal Cell Carcinoma?
Avishay Sella et al.
CHEMOTHERAPY (2012)
Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib
Julia Clemons et al.
CLINICAL GENITOURINARY CANCER (2012)
CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS: COSPONSORED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN THYROID ASSOCIATION
Jeffrey R. Garber et al.
ENDOCRINE PRACTICE (2012)
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
Yutaka Fujiwara et al.
INVESTIGATIONAL NEW DRUGS (2012)
Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
Doreen Braun et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
T3 preserves ovarian granulosa cells from chemotherapy-induced apoptosis
Cecilia Verga Falzacappa et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study
Valentina Baldazzi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
N. Shinohara et al.
BRITISH JOURNAL OF CANCER (2011)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
Yoshihiko Tomita et al.
EUROPEAN JOURNAL OF CANCER (2011)
Toxicities of Targeted Therapy and Their Management in Kidney Cancer
Giuseppe Di Lorenzo et al.
EUROPEAN UROLOGY (2011)
Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
Mariette H. W. Kappers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Guadalupe Aparicio-Gallego et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities
Christian Kollmannsberger et al.
ONCOLOGIST (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
Pazopanib: An Oral Multitargeted Tyrosine Kinase Inhibitor for Use in Renal Cell Carcinoma
Kourtney D. LaPlant et al.
ANNALS OF PHARMACOTHERAPY (2010)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Randa M. Abdulrahman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Noriko Makita et al.
THYROID (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Vascular Endothelial Growth Factor-targeted Therapy in Metastatic Renal Cell Carcinoma
Brian I. Rini
CANCER (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Frederic Illouz et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Role of type 3 deiodinase in cancer
Monica Dentice et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
2009 update on the classification of renal epithelial tumors in adults
Antonio Lopez-Beltran et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Thyroid Hormones Induce Cell Proliferation and Survival in Ovarian Granulosa Cells COV434
Cecilia Verga Falzacappa et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
I. Tamaskar et al.
ANNALS OF ONCOLOGY (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
New developments in multitargeted therapy for patients with solid tumours
C. Le Tourneau et al.
CANCER TREATMENT REVIEWS (2008)
Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling
Balazs Gereben et al.
ENDOCRINE REVIEWS (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of sunitinib on growth and function of FRTL-5 thyroid cells
Andrew K. Salem et al.
THYROID (2008)
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies
Doru T. Alexandrescu et al.
THYROID (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe et al.
LANCET ONCOLOGY (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
David H. Garfield et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome
Charles E. Schwartz et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
New insights into thyroid hormone action
Alexis Oetting et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Selective modulation of protein kinase a I and II reveals distinct roles in thyroid cell gene expression and growth
Davide Calebiro et al.
MOLECULAR ENDOCRINOLOGY (2006)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Anti-apoptotic effects of 3,5,3′-tri-iodothyronine in mouse hepatocytes
O. A. Sukocheva et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Association between development of hypothyroidism and improved survival in patients with head and neck cancer
Marc Nelson et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2006)
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer:: a review
P. Schoffski et al.
ANNALS OF ONCOLOGY (2006)
3,5,3′-triiodothyronine (T3) is a survival factor for pancreatic β-cells undergoing apoptosis
C Verga Falzacappa et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Thyroid hormone and breast carcinoma - Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma
M Cristofanilli et al.
CANCER (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Global increases in kidney cancer incidence, 1973-1992
A Mathew et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2002)
Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994):: National Health and Nutrition Examination Survey (NHANES III)
JG Hollowell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian sel-10 homolog
C Öberg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Caspase-3 gene knockout defines cell lineage specificity for programmed cell death signaling in the ovary
T Matikainen et al.
ENDOCRINOLOGY (2001)
分享论文
